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ABSTRACT
Introduction: The purpose of the present study
was to investigate the traceability of adverse
events (AEs) for branded and generic drugs with
identical nonproprietary names and to consider
potential implications for the traceability of AEs
for branded and biosimilar biologics.
Methods: Adverse event reports in the Food
and Drug Administration AE Reporting System
(FAERS) were compared with those in a
commercial insurance claims database (Truven
Health MarketScan) for 2 drugs (levetiracetam
and enoxaparin sodium) with manufacturing or
prescribing considerations potentially
analogous to those of some biosimilars.
Monthly rates of branded- and generic-
attributed AEs were estimated pre- and post-
generic entry. Post-entry branded-to-generic AE
relative rate ratios were calculated.
Results: In FAERS, monthly AE rate ratios
during the post-generic period showed a
pattern in which AE rates for the branded
products were greater than for the generic
products. Differences in rates of brand- and
generic-attributed AEs were statistically
significant for both study drugs; the AE rate
for the branded products peaked at
approximately 10 times that of the generic
levetiracetam products and approximately 4
times that of the generic enoxaparin sodium
products. In contrast, monthly ratios for the
MarketScan data were relatively constant over
time.
Conclusion: Use of the same nonproprietary
name for generic and branded products may
contribute to poor traceability of AEs reported
in the FAERS database due to the significant
misattribution of AEs to branded products
(when those AEs were in fact associated with
patient use of generic products). To ensure
accurate and robust safety surveillance and
traceability for biosimilar products in the
United States, improved product identification
mechanisms, such as related but distinguishable
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nonproprietary names for biosimilars and
reference biologics, should be considered.
Keywords: Adverse event attribution; Biologic;
Biosimilar; Drug traceability; Nonproprietary
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INTRODUCTION
Biologic therapies are medicinal products made
by or derived from the living cells of humans,
animals, or microorganisms [1]. Examples of
biologic therapies include vaccines, blood
products, cytokines, and monoclonal
antibodies. Biosimilars, or follow-on biologics,
are biologic therapies that are approved for
marketing on the basis of data demonstrating
that they have physicochemical and functional
characteristics comparable to those of a
previously licensed biologic therapy (i.e., the
reference biologic). The manufacturing process
for biologics, including biosimilars, is complex
and prevents biosimilars from being exact
replicas of the reference biologic. Differences
in manufacturing processes could lead to small
differences in a biosimilar’s overall efficacy and
safety profile, including immunogenicity [2–4],
which may not be detected in the abbreviated
clinical and non-clinical premarket studies
required for regulatory approval of the
biosimilar product [3, 5]. Differences between
a biosimilar and its reference product may also
emerge over time due to manufacturing
changes [6]. Further, biosimilars that share the
same reference product need not meet
regulatory standards of similarity with respect
to each other, and thus may have different
clinical profiles [7]. For these reasons, precise
post-market traceability of biosimilars and
reference biologics to further develop the
adverse event (AE) profiles of, and identify any
unexpected safety signals associated with, each
biosimilar product is a point of key interest to
health care providers, drug manufacturers,
regulators, and policymakers.
Whether biosimilars will or should be
considered interchangeable with their
reference biologics is a subject of debate [8–
10]. The pathway to approval of a biosimilar
therapy in the United States (US) is dictated by
the Biologics Price Competition and Innovation
Act of 2009 [7]. This legislation established a
standard for demonstrating that a proposed
product is ‘‘biosimilar to’’ the reference
biologic as well as a separate standard for
demonstrating that a biosimilar is
‘‘interchangeable’’ with the reference biologic
[7]. In the European Union (EU),
interchangeability is regulated at the Member
State level [2]. The potential for reference
biologics and biosimilars to be interchanged
by prescribers or substituted for one another by
pharmacists complicates traceability.
Experience with biosimilar therapies is
relatively limited. The EU was the first
jurisdiction to develop a robust regulatory
pathway for the approval of biosimilars. It
approved its first biosimilar, Omnitrope
(somatropin; Sandoz GmbH, Holzkirchen,
Germany), in 2006. No biosimilar products
have been approved in the US as of January,
2015, although a generic version of enoxaparin
sodium, a product that is regulated as a
biosimilar in the EU, was approved by the US
Food and Drug Administration (FDA) via the
standard generic drug (Abbreviated New Drug
Application) pathway in 2010. Experience from
biosimilars marketed in the EU emphasizes the
need for accurate tracking and tracing of
biologics, including biosimilars, so that their
safety can be adequately monitored post-market
[4, 11]. Misattribution of AEs to the reference
biologic rather than the responsible biosimilar
product (or vice versa) could result in an
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inaccurate safety profile for both products or
impede the identification and attribution of
safety signals.
In addition to distinct brand names and
batch numbers, another method to facilitate
differentiation and traceability of biosimilars
and reference biologics in the marketplace
would be to assign each biosimilar a
nonproprietary name that is related to, but
distinguishable from, the reference biologic’s
nonproprietary name. Several publications have
advised that using identical nonproprietary
names may complicate, and in some cases
thwart, post-market traceability of biologic
and biosimilar products [8, 11–14], including a
study that found that AEs reported in the FDA
AE Reporting System (FAERS) often are
attributed to the branded product when a
patient likely received a generic product with
the same nonproprietary name [14]. In the
present study, we aimed to further investigate
the traceability of AEs attributed to branded and
generic drugs. We selected 2 drugs,
levetiracetam and enoxaparin sodium, because
they have manufacturing or prescribing
considerations potentially analogous to those
of some biosimilars. We compared branded-to-
generic AE rates as reported in FAERS [15] to
those reported in an insurance claims database




We selected the antiepileptic drug levetiracetam
(reference products Keppra and Keppra XR;
UCB Inc., Smyrna, GA, USA) [17] and the low
molecular weight heparin (LMWH) enoxaparin
sodium (reference product Lovenox; Sanofi-
Aventis US LLC, Bridgewater, NJ, USA) [18].
Although FDA has rated these products as
therapeutically equivalent to their respective
reference products (unlike biosimilars, which
will likely not be interchangeable with their
reference biologics in some cases), for purposes
of this study, these products were considered
potentially analogous in certain respects to
biosimilars. Levetiracetam is considered a
narrow therapeutic index (NTI) drug by certain
insurers, including Medicaid [19], and the
European Medicines Agency considers the
follow-on version of enoxaparin sodium to be
a biosimilar, because of the potential for
considerable heterogeneity in the structure–
effect relationship [20]. In the absence of
approved biosimilars in the US, the intent here
was to use variability in pharmacokinetics and
structural complexity of these small-molecule
products as appropriate surrogates for the
clinical variability and heterogeneity expected
with respect to biosimilars and their reference
biologics (see online-only appendix for further
details on study drug selection). From the
perspective of AE monitoring, we would
expect more careful tracking for small-
molecule drugs with these characteristics.
Data Descriptions
FAERS
Food and Drug Administration maintains an
electronic information database, FAERS, to
assist its post-market safety surveillance
program for all approved small-molecule drugs
and therapeutic biologic products [15, 21].
FAERS data were used to estimate monthly
reported AEs attributed to the branded or
generic products of interest. Minimum data
elements for a FAERS submission are an
identifiable patient, an identifiable reporter, a
reaction or event, and a suspect drug [21].
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Truven Health MarketScan Commercial
Claims and Encounters and Medicare
Supplemental Database
The MarketScan database includes enrollment
history and claims for medical (provider and
institutional) and pharmacy services for a large
sample of[100 million unique de-identified
patients [16]. It reflects real-world practice by
capturing the full continuum of care across all
settings, including physician office visits;
hospital stays; and retail, mail order, and
specialty pharmacies. This database was used
to estimate the AEs attributed to the branded or
generic products of interest as well as the
number of monthly branded and generic
prescriptions for these products. Compared
with FAERS, the MarketScan database has
more strict requirements for product
identification. For example, drugs are
identified in the MarketScan database via
National Drug Codes (NDCs), which identify
the labeler, product, and trade package size of
each drug. As such, information such as the
specific strength, dosage form, and formulation
of a drug can be linked to each drug claim of a
patient. NDCs are not a mandatory part of AE
reports submitted to FAERS.
National Prescription AuditTM From IMS
Health Incorporated
The study was dependent upon availability of
prescribing data for the drugs studied: national
monthly prescription counts [22] and
MarketScan administrative claims data [16].
The number of branded and generic
prescriptions filled by month was obtained
from the National Prescription Audit (NPA) by
IMS Health Incorporated, which represents and
captures over 70% of all prescription activities in
the US and covers all products, classes, and
manufacturers [22]. We assumed that the
unknown number of prescriptions contributing
to AEs in FAERS is roughly proportional to the
branded and generic drugs’ market shares in the
IMS data.
AEs in the FAERS and MarketScan Data
Adverse events for each drug were identified
1 year before generic entry into the market and
for up to 2 years after generic entry (Fig. 1).
With the date of final FDA regulatory approval
as a proxy for entry into the market, 38 generic
products for levetiracetam and 3 generic
products for enoxaparin sodium were on the
US market during the study period (i.e., the first
2 years after first generic entry) (see Table S1,
online-only supplemental information).
Quarterly FAERS data were downloaded from
the FAERS website for the period between 2007
Q1 and 2012 Q3; events from the US were
identified and potential duplicate reports were
removed as per FAERS guidelines [23]. The
FAERS drug name variable was used to identify
reports associated with the study drugs. All drug
name values for reports remaining in this stage
of the sample selection were reviewed, and
reports corresponding to the study drugs (both
the branded and generic names) were identified.
Only those reports where one of these drugs was
identified as the primary suspect were included.
Potential misspellings of study drug names were
Fig. 1 Generic entry dates and study periods for
levetiracetam and enoxaparin sodium
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reviewed independently by two individuals to
minimize exclusion of AE reports in which a
study drug name was probably misspelled.
In the FAERS database, AEs are coded using
Medical Dictionary for Regulatory Activities
(MedDRA) terms; MedDRA is a clinically
validated international medical terminology
dictionary used by regulatory authorities. The
MarketScan database, in contrast, identifies
medical conditions by International
Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes. To
identify the equivalent AEs in the MarketScan
data, the MedDRA terms were mapped to ICD-9-
CM codes using software provided by the
Maintenance and Support Services
Organization [MedDRA Desktop Browser
3.0.2b, MedDRA Maintenance and Support
Services (MSSO), McLean, VA, USA] [24] and
an ICD-9-CM code list. AEs identified in the
FAERS database that did not have a suitable
ICD-9-CM code or that had an ICD-9-CM code
that was too broad (i.e., that would capture
many AEs in MarketScan that may not be
associated with the drug) were excluded. In
addition, AEs identified in the FAERS data that
were unlikely to be coded on a medical claim,
such as nausea, headache, or common colds,
were also excluded. To reduce noise further,
only AEs that are listed in the drug prescribing
information or those that were present in at
least 1% of the AE reports for the given drug in
the FAERS data were included. Similar MedDRA
terms were grouped into AE categories (e.g., the
following MedDRA terms were combined into
an anemia category: anemia, hemorrhagic
anemia, and iron deficiency anemia). Tables S2
and S3 (online-only supplemental information)
include the AE categories and corresponding
MedDRA terms and ICD-9-CM codes considered
for the two study drugs.
Patient-level counts of branded- or generic-
attributed AEs in FAERS were then summed to
calculate total monthly FAERS branded- or
generic-attributed AE counts; only one AE
category per report was counted (i.e., a report
containing multiple MedDRA terms from the
same category was counted as one AE). To
identify AEs in the MarketScan data, all medical
claims among patients with claims for the drugs
of interest were extracted. Among these,
medical claims for the AE categories for each
drug of interest (Tables S2 and S3, online) were
identified via relevant ICD-9-CM codes.
MarketScan medical claims for AEs during the
periods of interest were attributed to a particular
product at the patient level based on a patient’s
continuous possession of either the branded or
a generic drug. Specifically, claims for the
branded and generic products of interest were
identified via NDCs. See online-only appendix
for additional details concerning the
identification of AE claims and attribution.
Statistical Analysis
Food and Drug Administration AE Reporting
System AE rates were calculated as the total
monthly count of branded- or generic-
attributed AEs reported in the FAERS database
divided by the total number of branded or
generic prescriptions filled that month in the
IMS NPA database. The FAERS branded-to-
generic ratio of AEs for each month was
calculated as the brand-attributed rate of AEs
divided by the generic-attributed rate of AEs.
Likewise, MarketScan AE rates were calculated
as the total monthly MarketScan count of
branded- or generic-attributed AEs divided by
the total MarketScan count of branded or
generic prescriptions filled that month. The
MarketScan branded-to-generic ratio of AEs for
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each month was calculated as the brand-
attributed rate of AEs divided by the generic-
attributed rate of AEs.
To investigate how AE reporting varied
across time for the branded product both pre-
and post-generic entry date, the monthly rates
of brand- and generic-attributed AE rates in
both the FAERS and MarketScan data, as well as
an estimated monthly trend, were plotted.
Likewise, to investigate whether the brand-to-
generic AE rate ratios differ in FAERS data versus
the MarketScan data, the monthly brand-to-
generic AE rate ratios for the FAERS/IMS data
and MarketScan data as well as the monthly
estimated trend were also plotted.
To assess the changes in AE rates and rate
ratios over time, the trends in the data were
estimated. Exploratory data analysis revealed
that a parametric model to estimate the trend
(e.g., linear trend) may not provide a good fit to
the data. Accordingly, a trend was fitted to the
data using Locally Estimated Scatterplot
Smoother (LOESS), a technique often used to
estimate the trend in data over time when there
is no parametric trend in the data [25]. A robust
version of the algorithm resistant to the effects
of outliers was used. 95% confidence intervals
were constructed for the estimated trend from
the standard error estimates of the residuals
from the LOESS fit. Statistical analysis was
carried out using R (version 3.0.0, R
Foundation for Statistical Computing, Vienna,
Austria).
Statement of Ethics
Ethical approval was not required, as the data
analyzed were de-identified records from
regulatory or insurance databases. This article
does not contain any new studies with human
or animal subjects performed by the authors.
RESULTS
An overview of the number of AE reports and
prescriptions for levetiracetam and enoxaparin
sodium in both data sources is provided in
Table 1.
AE Rates for Levetiracetam
For the branded levetiracetam product in the
FAERS dataset, the monthly trend in the AE rate
was fairly constant during the period before
generic entry and steadily increased over the
two-year post-generic entry period (Fig. 2a). For
the generic levetiracetam products in the FAERS
dataset, the monthly AE rate steadily decreased
over time and stabilized approximately 1 year
after entry (Fig. 2a). In contrast to the FAERS
data, the monthly AE rates for the branded
levetiracetam product in the MarketScan claims
data were fairly constant for the entire 3-year
study period, and the AE rates of the branded
and generic levetiracetam products were
relatively constant during the 2-year post-
generic entry period (Fig. 2b). Figure 3
compares the ratio of the monthly brand AE
rate to the monthly generic AE rate for
levetiracetam during the post-generic period
Table 1 Overview of adverse event (AE) reports and




Claims data 93,006 175,837
Number of drug prescriptions
IMS NPA 16,247,074 8,143,747
Claims data 900,571 537,516
FAERS Food and Drug Administration AE Reporting
System, NPA National Prescription Audit
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for the two datasets. Although the ratios were
nearly constant in the claims dataset, the ratio
increased over time in the FAERS dataset; that
is, the monthly AE rate for the branded
levetiracetam product, was on average almost
10 times that of the generic products toward the
end of the study period. This difference in the
brand-to-generic AE rate ratios between the
FAERS and claims data was statistically
significant.
Fig. 2 Levetiracetam: monthly brand- and generic-attributed
adverse event rate and 95% conﬁdence intervals during the
pre- and post-generic entry periods. AE rates were calculated as
the total monthly count of branded- or generic-attributed
AEs divided by the total number of branded or generic
prescriptions ﬁlled that month. a FAERS. b Truven Health
MarketScan database. The dotted vertical line represents
introduction of generic levetiracetam; data points to the left of
the line represent the pre-generic period and data points to the
right of the line represent the post-generic period.FAERS Food
and Drug Administration Adverse Event Reporting System
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AE Rates for Enoxaparin Sodium
For enoxaparin sodium, the trends were similar
to those observed for levetiracetam but less
pronounced (in Figs. 4a, b, 5). In the FAERS
data, the monthly AE rates for the branded
product increased over time after generic entry,
whereas the monthly AE rates for the generic
products decreased and then stabilized over
time (Fig. 4a). In the MarketScan data, the
monthly AE rates were nearly constant for the
branded enoxaparin sodium product over the
three-year study period, and the monthly AE
rates of the generic enoxaparin sodium products
were relatively constant during the post-generic
period (Fig. 4b). The monthly AE rates ratios for
the FAERS data indicate that the ratio increased
and then stabilized to around 4 (i.e., the AE rate
for the branded enoxaparin sodium product was
4 times that of the generic products on average)
(Fig. 5). In contrast, the monthly ratios for the
claims data were almost constant over time.
These differences were statistically significant.
DISCUSSION
When comparing FAERS-derived branded- and
generic-attributed AEs against an insurance
claims data source that has more strict
requirements for product identification, one
would expect that the branded and generic AE
rates would be similar in both databases, given
that these products share the same active drug
substance and FDA has deemed them
therapeutically equivalent. Consistent with
this expectation, branded AE rates in a
nationally representative claims database were
nearly equal to those of the generic products
and remained constant after generic
introduction. The observed increase in
branded-to-generic AE ratio in the FAERS data,
in contrast, indicates that AEs in the FAERS
Fig. 3 FAERS and MarketScan adverse event rate ratios and 95% conﬁdence intervals for levetiracetam during the post-
generic entry period. FAERS Food and Drug Administration Adverse Event Reporting System
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database were frequently misattributed to the
branded product when a generic product was in
fact associated with the AEs. Our study, thus,
helps to confirm the findings of Lietzan et al.
[14], namely that AEs associated with generic
products are often misattributed to branded
products in FAERS data. These results suggest
that FAERS data may not provide reliable
traceability for generic drugs and their
branded reference products, which share the
Fig. 4 Enoxaparin sodium: monthly brand- and generic-
attributed adverse event rate and 95% conﬁdence intervals
during the pre- and post-generic entry periods. AE rates
were calculated as the total monthly count of branded- or
generic-attributed AEs divided by the total number of
branded or generic prescriptions ﬁlled that month.
a FAERS. b MarketScan. The dotted vertical line
represents introduction of generic enoxaparin sodium; data
points to the left of the line represent the pre-generic period
and data points to the right of the line represent the post-
generic period. FAERS Food and Drug Administration
Adverse Event Reporting System
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same nonproprietary name [14]. Moreover, a
recent publication also evaluated potential
misattribution AEs for enoxaparin generics in
passive (i.e., FAERS) and active (i.e., claims data)
surveillance [26]. The authors found that the
number of AE reports processed by generic
manufactures was much lower than expected
based on market share and the number of
events attributable to specific generic
enoxaparin products was approximately
ninefold lower than expected [26].
The nomenclature for biosimilars has been
debated in the US and internationally; however,
no formal policy has been announced by the
FDA as of January, 2015. Assuming that
biosimilars would be susceptible to FAERS
traceability issues similar to those found in our
study (i.e., misattribution of AEs where products
share the same nonproprietary name), our
results can provide guidance to policy makers
responsible for determining optimal
nomenclature for biosimilars. Our study
suggests that use of distinguishable
nonproprietary names for biosimilars and
reference biologics has the potential to
enhance drug traceability and
pharmacovigilance. Enhanced traceability in
FAERS data would be useful, because despite
that claims databases have strict product
identification requirements that facilitate
accurate AE attribution, they are not ideal for
detection of unexpected AEs. Our study suggests
that distinguishable nonproprietary names for
biosimilars may be one way to help promote the
attribution of AEs to the correct product [13,
27], assisting the identification and tracking of
safety information under the current system in
the US.
In a prior study that investigated the
traceability of products, including biosimilars,
in the EU’s EudraVigilance database, Vermeer
et al. [4] reported that the specific biologic was
identifiable in 96% of AE reports involving
suspected biologics for which a biosimilar was
Fig. 5 FAERS and MarketScan adverse event rate ratios and 95% conﬁdence intervals for enoxaparin sodium during the
post-generic entry period. FAERS Food and Drug Administration Adverse Event Reporting System
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available in the EU. This identification was
based on inclusion of either of the biologic’s
brand name or the biologic’s nonproprietary
name as well as the manufacturer name in
reports. The Vermeer et al. [4] study, however,
did not address the possibility that AEs may
have been misattributed to the wrong brand
name product or the wrong manufacturer. In
the same study, 79% of Eudra Vigilance reports
involving suspected biologics and 95% of Eudra
Vigilance reports for biosimilars identified by
product name lacked a batch number, which
highlights the challenges associated with
tracing AEs to the batch level [4].
In the AbbVie-sponsored study by Lietzan
et al. [14], which compared total brand-
attributed AEs in FAERS against total branded
prescriptions filled, the number of brand-
attributed AEs tended to remain the same or
increase as the total number of branded scripts
decreased for 6 of the 8 branded/generic
comparisons studied. The single NTI drug
studied failed to show a pattern of
misattribution of AEs to the branded product
after introduction of the generic product, and 1
drug did not have sufficient data post-generic
entry to determine whether a reliable trend
existed. For the remaining 6 products, the
increase in the ratio of brand-attributed AEs to
branded prescriptions suggested that many of
the AEs experienced by patients receiving the
generic products likely were incorrectly
reported as associated with the branded drug
[14]. The present study confirmed this pattern
of misattribution in the FAERS database for the
LMWH drug enoxaparin sodium and also the
NTI antiepileptic drug levetiracetam. Further,
the present study expanded on the findings of
Lietzan et al. [14] by demonstrating that the
pattern of misattribution observed in the FAERS
database did not occur in the nationally
representative MarketScan claims database, a
finding that was also reported in the Grampp
et al. [26] study of enoxaparin generics.
In contrast, a policy paper issued by the chief
scientific officer of Hospira [28] argues that
distinct brand names will ensure adequate
traceability of biosimilars and their reference
biologics. The commentary cites internal safety
reporting data for two biosimilars, RetacritTM
(epoetin alfa; Hospira, Lake Forest, IL, USA) and
NivestimTM (filgrastim; Hospira, Lake Forest, IL,
USA). It discusses Hospira’s post-market
pharmacovigilance data from the EU, in which
the suspect drug was identified by its brand
name in[99% of post-market reports for
Hospira’s erythropoietin biosimilar and[95%
of reports for Hospira’s filgrastim biosimilar
[28]. A potential bias of the Hospira study,
however, is that results were based on reports
received by the manufacturer and did not
include other sources such as EudraVigilance
[29]. When reporters notify the manufacturer of
an AE, they are likely confident that the suspect
drug is that manufacturer’s product; thus, this
method is subject to selection bias for reporters
who would not misattribute AEs. Moreover,
Hospira’s study did not address how many AE
reports associated with its biosimilars may have
been misattributed to the brand product or to
other biosimilars by brand name [28].
Considering these limitations, further evidence
is needed to support Hospira’s proposition that
distinct brand names will ensure effective
pharmacovigilance.
Limitations
Similar to the drugs studied in the analysis by
Lietzan et al. [14] and Grampp et al. [26], the
generic products investigated in the present
analysis have been rated by FDA as
therapeutically equivalent to their branded
reference products. AE misattribution,
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therefore, may be greater for these products
compared with biologics that FDA does not
deem interchangeable. With therapeutically
equivalent products, AE reporters may perceive
that it is less important to specify the particular
product when reporting an AE or may not be
aware that a substitution actually occurred.
Likewise, it is possible that reporters may be
more vigilant with regard to AE attribution for
biosimilars, and misattribution rates could be
lower with respect to biosimilars than observed
in our study.
Another potential limitation is that some of
the AE reports actually attributable to branded
products in the FAERS database in the present
study could have been identified only by generic
name. Such cases would lead to a lower branded
AE rate relative to the generic AE rate. Evidence
from Lietzan et al. [14], Grampp et al. [26], and
the present study, however, suggests that AE
misattribution is likely to be more common in
the other direction; that is, AEs associated with
generic drugs are more likely to be reported by
brand name.
The temporal reporting of prescriptions filled
and the occurrence of an AE is the only way to
directly link an AE to a specific drug in claims
data. Thus, it is possible that some of the AEs
attributed to the respective drugs in the
MarketScan database may have been unrelated
to the study drugs. The impact of this
occurrence is probably minimal, for there is no
reason to suspect bias in favor of branded vs.
generic drugs.
Our study examined only data in the 1 year
pre- and 2 years post-generic entry; it is possible
that longer term data could have yielded more
robust findings. Finally, our study used an
assumption that the unknown number of
prescriptions contributing to AEs in FAERS was
proportional to the branded and generic drug
market share in IMS. This assumption was based
on the fact that IMS is a national representative
sampling of prescription drug sales and, thus, is
the best source available for such a calculation.
CONCLUSION
Results of the present study may have
implications for the traceability of biosimilars
once they enter the US market. To ensure
accurate and robust safety surveillance and
traceability for biosimilar products in the US,
improved product identification mechanisms,
such as related but distinguishable
nonproprietary names for biosimilars and
reference biologics, should be considered.
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